ID

29694

Beschreibung

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3); ODM derived from: https://clinicaltrials.gov/show/NCT00420784

Link

https://clinicaltrials.gov/show/NCT00420784

Stichworte

Versionen (1)
  1. 13.04.18 13.04.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

13. April 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Hepatitis C NCT00420784

Englisch

Eligibility Hepatitis C NCT00420784

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
males and females between 18 and 70 years old
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
detectable plasma hepatitis c virus (hcv) ribonucleic acid (rna) greater than or equal to (>=) 10,000 international units per milliliter (iu/ml)
Beschreibung

Plasma Hepatitis C virus RNA Detectable IU/mL

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0032105
UMLS CUI [1,2]
C0369335
UMLS CUI [1,3]
C3830527
UMLS CUI [1,4]
C0439458
must have chronic hepatitis c (genotype 1) and have already received at least one prior course of pegylated interferon alfa 2a with ribavirin
Beschreibung

Chronic Hepatitis C Genotype | Peginterferon alfa-2a Course Quantity | Ribavirin

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0524910
UMLS CUI [1,2]
C0017431
UMLS CUI [2,1]
C0391001
UMLS CUI [2,2]
C0750729
UMLS CUI [2,3]
C1265611
UMLS CUI [3]
C0035525
cannot also be infected with human immunodeficiency virus or hepatitis b
Beschreibung

HIV Infection Absent | Hepatitis B Absent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0019693
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0019163
UMLS CUI [2,2]
C0332197
must be judged to be in general good health and able to receive pegasys® and copegus®
Beschreibung

General health good | Pegasys Receive Ability | Copegus Receive Ability

Datentyp

boolean

Alias
UMLS CUI [1]
C1277245
UMLS CUI [2,1]
C1176430
UMLS CUI [2,2]
C1514756
UMLS CUI [2,3]
C0085732
UMLS CUI [3,1]
C1170183
UMLS CUI [3,2]
C1514756
UMLS CUI [3,3]
C0085732
no drug or alcohol abuse in the last year
Beschreibung

Substance Use Disorders Absent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0038586
UMLS CUI [1,2]
C0332197
must agree to use two effective methods of birth control during the study and for 6 months after you stop taking study medication. one of the methods needs to be a
Beschreibung

Contraceptive methods Quantity

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0700589
UMLS CUI [1,2]
C1265611
'barrier' method (condom or diaphragm)
Beschreibung

Contraception, Barrier | Condom | Vaginal contraceptive diaphragm

Datentyp

boolean

Alias
UMLS CUI [1]
C0004764
UMLS CUI [2]
C0677582
UMLS CUI [3]
C0042241
if you are a woman, you cannot be in this study if you are pregnant or nursing
Beschreibung

Gender | Pregnancy Absent | Breast Feeding Absent

Datentyp

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2,1]
C0032961
UMLS CUI [2,2]
C0332197
UMLS CUI [3,1]
C0006147
UMLS CUI [3,2]
C0332197
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
participation in any clinical trial of a hcv protease inhibitor of any duration
Beschreibung

Study Subject Participation Status | HCV Protease Inhibitors

Datentyp

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2,1]
C0220847
UMLS CUI [2,2]
C0033607
prior response to therapy and failure to achieve svr which was due to treatment non-compliance
Beschreibung

Disease Response | Sustained Virologic Response failed | Compliance behavior Lacking

Datentyp

boolean

Alias
UMLS CUI [1]
C1704632
UMLS CUI [2,1]
C4050171
UMLS CUI [2,2]
C0231175
UMLS CUI [3,1]
C1321605
UMLS CUI [3,2]
C0332268
any other cause of significant liver disease in addition to hepatitis c; this may include but is not limited to, hepatitis b, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, wilson's disease, nonalcoholic steatohepatitis, or primary biliary cirrhosis
Beschreibung

Cause Liver disease | Hepatitis B | Drug-induced cirrhosis of liver | Liver Cirrhosis, Alcoholic | Hepatitis, Autoimmune | Hemochromatosis | Hepatolenticular Degeneration | Nonalcoholic Steatohepatitis | Primary biliary cirrhosis

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0015127
UMLS CUI [1,2]
C0023895
UMLS CUI [2]
C0019163
UMLS CUI [3]
C1960179
UMLS CUI [4]
C0023891
UMLS CUI [5]
C0241910
UMLS CUI [6]
C0018995
UMLS CUI [7]
C0019202
UMLS CUI [8]
C3241937
UMLS CUI [9]
C0008312
diagnosed or suspected hepatocellular carcinoma
Beschreibung

Liver carcinoma | Liver carcinoma Suspected

Datentyp

boolean

Alias
UMLS CUI [1]
C2239176
UMLS CUI [2,1]
C2239176
UMLS CUI [2,2]
C0750491
history of or current evidence of decompensated liver disease
Beschreibung

Decompensated liver disease

Datentyp

boolean

Alias
UMLS CUI [1]
C4075847
participation in any clinical trial of an investigational drug within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study)
Beschreibung

Study Subject Participation Status | Investigational New Drugs

Datentyp

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Hepatitis C NCT00420784

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
males and females between 18 and 70 years old
boolean
C0001779 (UMLS CUI [1])
Plasma Hepatitis C virus RNA Detectable IU/mL
Item
detectable plasma hepatitis c virus (hcv) ribonucleic acid (rna) greater than or equal to (>=) 10,000 international units per milliliter (iu/ml)
boolean
C0032105 (UMLS CUI [1,1])
C0369335 (UMLS CUI [1,2])
C3830527 (UMLS CUI [1,3])
C0439458 (UMLS CUI [1,4])
Chronic Hepatitis C Genotype | Peginterferon alfa-2a Course Quantity | Ribavirin
Item
must have chronic hepatitis c (genotype 1) and have already received at least one prior course of pegylated interferon alfa 2a with ribavirin
boolean
C0524910 (UMLS CUI [1,1])
C0017431 (UMLS CUI [1,2])
C0391001 (UMLS CUI [2,1])
C0750729 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0035525 (UMLS CUI [3])
HIV Infection Absent | Hepatitis B Absent
Item
cannot also be infected with human immunodeficiency virus or hepatitis b
boolean
C0019693 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0019163 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
General health good | Pegasys Receive Ability | Copegus Receive Ability
Item
must be judged to be in general good health and able to receive pegasys® and copegus®
boolean
C1277245 (UMLS CUI [1])
C1176430 (UMLS CUI [2,1])
C1514756 (UMLS CUI [2,2])
C0085732 (UMLS CUI [2,3])
C1170183 (UMLS CUI [3,1])
C1514756 (UMLS CUI [3,2])
C0085732 (UMLS CUI [3,3])
Substance Use Disorders Absent
Item
no drug or alcohol abuse in the last year
boolean
C0038586 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Contraceptive methods Quantity
Item
must agree to use two effective methods of birth control during the study and for 6 months after you stop taking study medication. one of the methods needs to be a
boolean
C0700589 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Contraception, Barrier | Condom | Vaginal contraceptive diaphragm
Item
'barrier' method (condom or diaphragm)
boolean
C0004764 (UMLS CUI [1])
C0677582 (UMLS CUI [2])
C0042241 (UMLS CUI [3])
Gender | Pregnancy Absent | Breast Feeding Absent
Item
if you are a woman, you cannot be in this study if you are pregnant or nursing
boolean
C0079399 (UMLS CUI [1])
C0032961 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0006147 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
Item Group
C0680251 (UMLS CUI)
Study Subject Participation Status | HCV Protease Inhibitors
Item
participation in any clinical trial of a hcv protease inhibitor of any duration
boolean
C2348568 (UMLS CUI [1])
C0220847 (UMLS CUI [2,1])
C0033607 (UMLS CUI [2,2])
Disease Response | Sustained Virologic Response failed | Compliance behavior Lacking
Item
prior response to therapy and failure to achieve svr which was due to treatment non-compliance
boolean
C1704632 (UMLS CUI [1])
C4050171 (UMLS CUI [2,1])
C0231175 (UMLS CUI [2,2])
C1321605 (UMLS CUI [3,1])
C0332268 (UMLS CUI [3,2])
Cause Liver disease | Hepatitis B | Drug-induced cirrhosis of liver | Liver Cirrhosis, Alcoholic | Hepatitis, Autoimmune | Hemochromatosis | Hepatolenticular Degeneration | Nonalcoholic Steatohepatitis | Primary biliary cirrhosis
Item
any other cause of significant liver disease in addition to hepatitis c; this may include but is not limited to, hepatitis b, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, wilson's disease, nonalcoholic steatohepatitis, or primary biliary cirrhosis
boolean
C0015127 (UMLS CUI [1,1])
C0023895 (UMLS CUI [1,2])
C0019163 (UMLS CUI [2])
C1960179 (UMLS CUI [3])
C0023891 (UMLS CUI [4])
C0241910 (UMLS CUI [5])
C0018995 (UMLS CUI [6])
C0019202 (UMLS CUI [7])
C3241937 (UMLS CUI [8])
C0008312 (UMLS CUI [9])
Liver carcinoma | Liver carcinoma Suspected
Item
diagnosed or suspected hepatocellular carcinoma
boolean
C2239176 (UMLS CUI [1])
C2239176 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
Decompensated liver disease
Item
history of or current evidence of decompensated liver disease
boolean
C4075847 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs
Item
participation in any clinical trial of an investigational drug within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study)
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video